Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.255
-0.105 (-3.12%)
At close: Dec 12, 2025, 4:00 PM EST
3.250
-0.005 (-0.15%)
After-hours: Dec 12, 2025, 4:00 PM EST
Aclaris Therapeutics Employees
As of December 31, 2024, Aclaris Therapeutics had 64 total employees, including 61 full-time and 3 part-time employees. The number of employees decreased by 27 or -29.67% compared to the previous year.
Employees
64
Change (1Y)
-27
Growth (1Y)
-29.67%
Revenue / Employee
$245,969
Profits / Employee
-$2,213,750
Market Cap
352.66M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64 | -27 | -29.67% |
| Dec 31, 2023 | 91 | -14 | -13.33% |
| Dec 31, 2022 | 105 | 28 | 36.36% |
| Dec 31, 2021 | 77 | 17 | 28.33% |
| Dec 31, 2020 | 60 | -17 | -22.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACRS News
- 17 days ago - Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Aclaris Therapeutics to Participate in Three November Healthcare Conferences - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics, Inc. - Special Call - Seeking Alpha
- 2 months ago - Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics to Participate in Two September Healthcare Conferences - GlobeNewsWire
- 4 months ago - Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire